BU-NOT-SET

CONTACT US
The QbD approach: Key advantages in clinical and commercial phases
  • Analytical chemistry
Lab
Insight
Sustainability report 2020
  • Sustainability
Report
Report
Recipharm and Oncopeptides: Successful collaboration in the development of melflufen, a peptidase-potentiated alkylating agent in clinical trials
  • Drug substance
Man at poster
Poster
Recipharm Analytical Solutions™
  • Analytical chemistry
Icon
Fact sheet
Impurity identification
  • Analytical chemistry
Woman inserting vials in machine
Fact sheet
Stability studies
  • Analytical chemistry
hand holding vials plate
Fact sheet
Extractables & leachables testing
  • Analytical chemistry
Product mix
Fact sheet
Pharmaceutical mergers and acquisitions: opportunities and drivers for CDMOs
  • Industry trends
Eyes
Insight
Global expansion in the CDMO field
  • Industry trends
Eyes
Insight
Webinar
  • Analytical chemistry
  • Drug product
Ensuring stability excellence for global consumer and OTC products
Insight
  • Industry trends
The impact of the COVID-19 pandemic on global pharmaceutical growth
Insight
  • Industry trends
COVID-19: a year of unprecedented change
Insight
  • Drug product
Oral solids: market and technology trends
Fact sheet
  • Drug product
Oral modified release
Fact sheet
  • Drug product
Semi-solids an overview of current regulatory requirement
Insight
  • Drug substance
API relocation strategies for CDMO’s
Fact sheet
  • Drug product
  • Manufacturing
Clinical trial material
Insight
  • Drug substance
Time and cost-effective solubility improvement